Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage

Hypertension Research

Volumn 33, Issue 2, 2010, Pages 98-104

  Funke Kaiser, Heiko ^a   Zollmann, Frank S ^a   Schefe, Jan H ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

(pro)renin receptor; Promyelocytic zinc finger protein; Renin angiotensin system; Renin prorenin receptor blockers; Signal transduction

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HANDLE REGION PEPTIDE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROMYELOCYTIC ZINC FINGER PROTEIN; PRORENIN; PRORENIN RECEPTOR; PROTEIN CAPER; PROTEIN P85; PROTEIN P85ALPHA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RECEPTOR BLOCKING AGENT; RENIN; RENIN INHIBITOR; RENIN PRORENIN RECEPTOR BLOCKER; UNCLASSIFIED DRUG; VALSARTAN; ZINC FINGER PROTEIN;

APOPTOSIS; BINDING COMPETITION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; EMBRYO DEVELOPMENT; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLOMERULOSCLEROSIS; HEART MUSCLE FIBROSIS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA RENIN ACTIVITY; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; RECEPTOR BINDING; RENIN RELEASE; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 76349122414     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.206     Document Type: Review

References (98)

1. Re RN. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42: 117-122.
2. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
3. Nguyen G, Burckle CA, Sraer JD. Renin/prorenin-receptor biochemistry and functional significance. Curr Hypertens Rep 2004; 6: 129-132.
4. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-1366.
5. Costoya JA, Pandolfi PP. The role of promyelocytic leukemia zinc finger and promye-locytic leukemia in leukemogenesis and development. Curr Opin Hematol 2001; 8: 212-217.
6. Senbonmatsu T, Saito T, Landon EJ, Watanabe O, Price Jr E, Roberts RL, Imboden H, Fitzgerald TG, Gaffney FA, Inagami T. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J 2003; 22: 6471-6482.
7. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19: 2537-2548.
8. Schefe JH, Neumann C, Goebel M, Danser J, Kirsch S, Gust R, Kintscher U, Unger T, Funke-Kaiser H. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens 2008; 26: 1787-1794.
9. Ramser J, Abidi FE, Burckle CA, Lenski C, Toriello H, Wen G, Lubs HA, Engert S, Stevenson RE, Meindl A, Schwartz CE, Nguyen G. A unique exonic splice enhancer mutation in a family with x-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum Mol Genet 2005; 14: 1019-1027.
10. Otis M, Campbell S, Payet MD, Gallo-Payet N. Angiotensin II stimulates protein synthesis and inhibits proliferation in primary cultures of rat adrenal glomerulosa cells. Endocrinology 2005; 146: 633-642.
11. Yoeli-Lerner M, Toker A. Akt/pkb signaling in cancer: a function in cell motility and invasion. Cell Cycle 2006; 5: 603-605.
12. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postcondi-tioning. Cardiovasc Res 2006; 70: 240-253.
13. Ko JH, Son W, Bae GY, Kang JH, Oh W, Yoo OJ. A new hepatocytic isoform of plzf lacking the btb domain interacts with atp7b, the wilson disease protein, and positively regulates erk signal transduction. J Cell Biochem 2006; 99: 719-734.
14. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelly KA, Yuen D, Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H, Gilbert RE. The (pro)renin receptor: site-specific and functional linkage to the vacuolar h+-atpase in the kidney. Hypertension 2009; 54: 261-269.
15. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, Fehr S, Stahl RA, Garrelds IM, Danser AH, van Goor H, Contrepas A, Nguyen G, Wenzel U. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of goldblatt hypertensive rats. Kidney Int 2007; 72: 725-730.
16. Hamming I, Contrepas A, Nguyen G, Huitema S, Navis GJ, van Goor H. Regulation of the renal renin/ prorenin receptor by ACE inhibition and sodium restriction. Poster no. 22. Gordon Research Conference on Angiotensin, September 10-15, 2006, Aussois, France.
17. Wilkinson-Berka JL, Heine R, Tan G, Tikellis C, Cooper ME, Nguyen G, Miller AG. The role of the (pro)renin receptor in developing ischaemic and diabetic retina. J Renin Angiotensin Aldosterone Syst 2008; 9(Supplement 1): S8.
18. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin at1 receptor and NADPH oxidase activity. Exp Physiol 2008; 93: 709-714.
19. Amsterdam A, Nissen RM, Sun Z, Swindell EC, Farrington S, Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc Natl Acad Sci USA 2004; 101: 12792-12797.
20. Bader M. The (pro)renin receptor, (P)RR/ ATP6AP2, a bifunctional protein? J Renin Angiotensin Aldosterone Syst 2008; 9(Supplement 1): S5.
21. Guidelines committee. 2003 european society of hypertension-european society of cardiology guidelines for the management of arterial hypertension. J Hypertens 21; 2003: 1011-1053.
22. Cutler JA. High blood pressure and end-organ damage. J Hypertens Suppl 1996; 14: S3-S6.
23. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5: 167-173.
24. Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens 2005; 14: 448-452.
25. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl 2005; 94: S14-S18.
26. Agodoa LY, Jones CA, Held PJ. End-stage renal disease in the USA: data from the united States Renal Data System. Am J Nephrol 1996; 16: 7-16.
27. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006; 60: 1471-1483.
28. Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone 2003; 5: 12-21.
29. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108: 2347-2357.
30. Banerjee D, Materson BJ. Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. Curr Hypertens Rep 2002; 4: 445-452.
31. Sleight P. Angiotensin II and trials of Cardiovascular Outcomes. Am J Cardiol 2002; 89: 11A-16A; discussion 16A-17A.
32. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-1961.
33. Ichihara A, Kaneshiro Y, Takemitsu T, Suzuki F, Nakagawa T, Nishiyama A, Iwata H, Ishida Y, Inagami T, Saruta T, Hayashi M. 'Receptor-associated prorenin system' contributes to hypertensive end-organ damage. J Hypertens 2005; 23 (suppl 2): S78, P1.197.
34. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
35. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
36. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
37. Burckle CA, Jan Danser AH, Muller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006; 47: 552-556.
38. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-indepen-dent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795.
39. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-688.
40. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burckle CA, Muller DN, Bader M, Nguyen G, Danser AH. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25: 2441-2453.
41. 00 peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-681.
42. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Itoh H. Drug discovery for overcoming chronic kidney disease (CKD): new therapy for CKD by a (pro)renin-receptor-blocking decoy peptide. J Pharmacol Sci 2009; 109: 20-23.
43. Danser AJ, Nguyen G. The Renin academy summit: advancing the understanding of renin science. J Renin Angiotensin Aldosterone Syst 2008; 9: 119-123.
44. Danser AHJ. Prorenin, the (Pro)renin Receptor, and Renin Inhibition. Chapter 4, pp 1-20 In: Hollenberg NK (ed), Braunwald E (Series ed). Atlas of Hypertension, 6th edn CMG (Current Medicine Group) LLC, a division of Springer Science+Business Media LLC: Philadelphia, 2009. pp 19106-192352.
45. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Decoy peptide' region (riflkrmpsi) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int J Mol Med 2009; 24: 83-89.
46. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am J Physiol Heart Circ Physiol 2008; 295: H1117-H1121.
47. Shan Z, Cuadra AE, Sumners C, Raizada MK. Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol 2008; 93: 701-708.
48. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Itoh H, Oike Y, Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007; 48: 422-429.
49. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angio-tensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009; 58: 1625-1633.
50. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98: 1966-1970.
51. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, Lorenz G, Rettig R, Mullins JJ, Peters J. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26: 102-109.
52. Peters J, Schluter T, Riegel T, Peters BS, Beineke A, Maschke U, Hosten N, Mullins JJ, Rettig R. Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism. Am J Physiol Heart Circ Physiol 2009; 297: H1845-H1852.
53. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ, Mitchell KD. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 trans-genic rats with inducible ang ii-dependent malignant hypertension. Am J Physiol Renal Physiol 2007; 292: F1858-F1866.
54. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 2009; 53: 1062-1069.
55. Campbell DJ, Karam H, Menard J, Bruneval P, Mullins JJ. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 2009; 54: 1248-1253.
56. Prescott G, Silversides DW, Reudelhuber TL. Tissue activity of circulating prorenin. Am J Hypertens 2002; 15: 280-285.
57. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
58. Wilson DM, Luetscher JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1101-1106.
59. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents 2003; 13: 589-603.
60. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
61. Hershey JC, Steiner B, Fischli W, Feuerstein G. Renin inhibitors: an antihypertensive strategy on the vergeof reality. Drug Discov Today: Therapeutic Strategies 2005; 2: 181-185.
62. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (spp100): comparison with enalapril. Hypertension 2002; 39: e1-e8.
63. Verburg KM, Kleinert HD, Kadam JR, Chekal MA, Mento PF, Wilkes BM. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys. Hypertension 1989; 13: 262-272.
64. Boger RS, Glassman HN, Cavanaugh JH, Schmitz PJ, Lamm J, Moyse D, Cohen A, Kleinert HD, Luther RR. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension 1990; 15: 835-840.
65. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskirentherapy. Hypertension 2008; 51: 15-18.
66. Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25: 1775-1782.
67. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1151-1157.
68. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the at1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-3133.
69. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-597.
70. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low pra levels or whose pra falls insufficiently or reactively rises. Am J Hypertens 2009; 22: 112-121.
71. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high-and low-baseline pra levels, respectively. Am J Hypertens 2009; 22: 954-957.
72. Schalekamp MA, Derkx FH, Deinum J, Danser AJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens 2008; 26: 928-937.
73. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69: 1503-1506.
74. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008; 51: 1259-1264.
75. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker hrp fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008; 19: 743-748.
76. Hirose T, Hashimoto M, Totsune K, Metoki H, Asayama K, Kikuya M, Sugimoto K, Katsuya T, Ohkubo T, Hashimoto J, Rakugi H, Takahashi K, Imai Y. Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens 2009; 22: 294-299.
77. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP, Janzer RC, Corvol P, Gasc JM. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004; 90: 1059-1068.
78. Ludwig J, Kerscher S, Brandt U, Pfeiffer K, Getlawi F, Apps DK, Schagger H. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-atpase from chromaffin granules. J Biol Chem 1998; 273: 10939-10947.
79. Nelson N, Harvey WR. Vacuolar and plasma membrane proton- adenosinetriphospha-tases. Physiol Rev 1999; 79: 361-385.
80. Bader M. The second life of the (pro)renin receptor. J Renin Angiotensin Aldosterone Syst 2007; 8: 205-208.
81. Liang P, Jones CA, Bisgrove BW, Song L, Glenn ST, Yost HJ, Gross KW. Genomic characterization and expression analysis of the first nonmammalian renin genes from zebrafish and pufferfish. Physiol Genomics 2004; 16: 314-322.
82. Endo Y, Chen M, Vallon V, Schnermann J, Briggs JP. Expression of cathepsin D and angiotensinogen in nephrons of zebrafish (Danio rerio) kidney. Bull Mt Desert Island Biol Lab 2000; 38: 31-32.
83. Saris JJ, t Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-571.
84. Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, Crowell DN. Prenylation of oncogenic human ptp(caax) protein tyrosine phosphatases. Cancer Lett 1996; 110: 49-55.
85. Wang J, Kirby CE, Herbst R. The tyrosine phosphatase prl-1 localizes to the endoplas-mic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem 2002; 277: 46659-46668.
86. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009; 53: 1077-1082.
87. Praizovic NG, Contrepas AN, Muller L, Corvol P, Nguyen G. Intracellular localization and processing of the (pro)renin receptor. Abstract P85, 61st Annual High Blood Pressure Research Conference. Westin La Paloma, Tuscon, AZ, September 26-29, 2007.
88. Lee-Kirsch MA, Gaudet F, Cardoso MC, Lindpaintner K. Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing. Circ Res 1999; 84: 240-246.
89. Sinn PL, Sigmund CD. Identification of three human renin mrna isoforms from alternative tissue-specific transcriptional initiation. Physiol Genomics 2000; 3: 25-31.
90. Clausmeyer S, Sturzebecher R, Peters J. An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria. Circ Res 1999; 84: 337-344.
91. Peters J, Clausmeyer S. Intracellular sorting of renin: cell type specific differences and their consequences. J Mol Cell Cardiol 2002; 34: 1561-1568.
92. Wanka H, Kessler N, Ellmer J, Endlich N, Peters BS, Clausmeyer S, Peters J. Cytosolic renin is targeted to mitochondria and induces apoptosis in H9c2 rat cardiomyoblasts. J Cell Mol Med 2009; 13: 2926-2937.
93. Clausmeyer S, Reinecke A, Farrenkopf R, Unger T, Peters J. Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. Endocrinology 2000; 141: 2963-2970.
94. Xu D, Borges GR, Grobe JL, Pelham CJ, Yang B, Sigmund CD. Preservation of intracellular renin expression is insufficient to compensate for genetic loss of secreted renin. Hypertension 2009; 54: 1240-1247.
95. Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003; 2: 369-378.
96. Wang N, Satonaka H, Frank GD, Wicks K, Rachakonda A, Ding R, Landon EJ, Pandolfi PP, Inagami T. Abstract O13 Annual High Blood Pressure Research Conference. Tuscon, 2007.
97. Seda O, Liska F, Sedova L, Kazdova L, Krenova D, Kren V. A 14-gene region of rat chromosome 8 in shr-derived polydactylous congenic substrain affects muscle-specific insulin resistance, dyslipidaemia and visceral adiposity. Folia Biol (Praha) 2005; 51: 53-61.
98. Naray-Fejes-Toth A, Boyd C, Fejes-Toth G. Regulation of epithelial sodium transport by promyelocytic leukemia zinc finger protein. Am J Physiol Renal Physiol 2008; 295: F18-F26.